Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Negatively charged phospholipid surfaces, primarily characterized by the presence of externalized phosphatidylserine (PS), serve as critical physiological and pathological signaling platforms. In healthy cells, flippase enzymes maintain these anionic lipids on the inner leaflet of the plasma membrane; however, during apoptosis, cellular stress, or oncogenic transformation, PS is translocated to the outer leaflet (Birge et al., 2016, Cell Death & Differentiation). This externalization creates a procoagulant surface that facilitates the assembly of tenase and prothrombinase complexes, essential for blood clotting (Lentz, 2003, Thrombosis and Haemostasis). In the context of oncology, these surfaces act as a global immunosuppressive signal in the tumor microenvironment, inhibiting the maturation of dendritic cells and promoting an M2-like anti-inflammatory macrophage phenotype (Thorpe, 2010, Journal of Controlled Release). Therapeutic strategies involve using antibodies like bavituximab to mask these surfaces and restore anti-tumor immunity or utilizing PS-binding proteins like Annexin V for the molecular imaging of cell death (Belhocine et al., 2004, Clinical Cancer Research). Furthermore, certain viruses exploit these negatively charged surfaces through 'apoptotic mimicry' to gain entry into host cells.
Binding to externalized anionic phospholipids to block immunosuppressive signaling, induce antibody-dependent cellular cytotoxicity (ADCC), or provide a scaffold for the assembly of procoagulant complexes.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Negatively charged phospholipid surfaces (PS-rich surfaces).